These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 9118043

  • 1. A case-matched molecular comparison of extraovarian versus primary ovarian adenocarcinoma.
    Kowalski LD, Kanbour AI, Price FV, Finkelstein SD, Christopherson WA, Seski JC, Naus GJ, Burnham JA, Kanbour-Shakir A, Edwards RP.
    Cancer; 1997 Apr 15; 79(8):1587-94. PubMed ID: 9118043
    [Abstract] [Full Text] [Related]

  • 2. Overexpression of HER-2/neu is not a risk factor in ovarian clear cell adenocarcinoma.
    Tanabe H, Nishii H, Sakata A, Suzuki K, Mori Y, Shinozaki H, Watanabe A, Ochiai K, Yasuda M, Tanaka T.
    Gynecol Oncol; 2004 Sep 15; 94(3):735-9. PubMed ID: 15350366
    [Abstract] [Full Text] [Related]

  • 3. p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes.
    Zheng W, Cao P, Zheng M, Kramer EE, Godwin TA.
    Gynecol Oncol; 1996 May 15; 61(2):167-74. PubMed ID: 8626128
    [Abstract] [Full Text] [Related]

  • 4. p53 mutation is infrequent in clear cell carcinoma of the ovary.
    Ho ES, Lai CR, Hsieh YT, Chen JT, Lin AJ, Hung MH, Liu FS.
    Gynecol Oncol; 2001 Feb 15; 80(2):189-93. PubMed ID: 11161858
    [Abstract] [Full Text] [Related]

  • 5. Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas.
    Khalifa MA, Mannel RS, Haraway SD, Walker J, Min KW.
    Gynecol Oncol; 1994 Apr 15; 53(1):84-92. PubMed ID: 7909788
    [Abstract] [Full Text] [Related]

  • 6. Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms.
    Wu Y, Soslow RA, Marshall DS, Leitao M, Chen B.
    Gynecol Oncol; 2004 Dec 15; 95(3):570-5. PubMed ID: 15581965
    [Abstract] [Full Text] [Related]

  • 7. p53 and HER-2/neu overexpression in ovarian borderline tumors.
    Eltabbakh GH, Belinson JL, Kennedy AW, Biscotti CV, Casey G, Tubbs RR.
    Gynecol Oncol; 1997 May 15; 65(2):218-24. PubMed ID: 9159328
    [Abstract] [Full Text] [Related]

  • 8. Clinical and molecular differences between clear cell and papillary serous ovarian carcinoma.
    Eltabbakh GH, Mount SL, Beatty B, Simmons-Arnold L, Cooper K.
    J Surg Oncol; 2006 Apr 01; 93(5):379-86. PubMed ID: 16550573
    [Abstract] [Full Text] [Related]

  • 9. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL, Shen DH, Xue WC, Li Y, Yu YZ.
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr 01; 42(4):227-32. PubMed ID: 17631760
    [Abstract] [Full Text] [Related]

  • 10. c-FLIPL expression defines two ovarian cancer patient subsets and is a prognostic factor of adverse outcome.
    Bagnoli M, Ambrogi F, Pilotti S, Alberti P, Ditto A, Barbareschi M, Galligioni E, Biganzoli E, Canevari S, Mezzanzanica D.
    Endocr Relat Cancer; 2009 Jun 01; 16(2):443-53. PubMed ID: 19321593
    [Abstract] [Full Text] [Related]

  • 11. Comparative immunohistochemical studies of bcl-2 and p53 proteins in benign and malignant ovarian endometriotic cysts.
    Nezhat F, Cohen C, Rahaman J, Gretz H, Cole P, Kalir T.
    Cancer; 2002 Jun 01; 94(11):2935-40. PubMed ID: 12115382
    [Abstract] [Full Text] [Related]

  • 12. [Expression of P53, P63, and C-erbB-2 in endometrioid adenocarcinoma and their clinicopathological significance].
    Hu WF, Liu MQ, Zhao Q.
    Ai Zheng; 2004 Sep 01; 23(9):1021-5. PubMed ID: 15363194
    [Abstract] [Full Text] [Related]

  • 13. Molecular and cytokinetic pretreatment risk assessment in endometrial carcinoma.
    Silverman MB, Roche PC, Kho RM, Keeney GL, Li H, Podratz KC.
    Gynecol Oncol; 2000 Apr 01; 77(1):1-7. PubMed ID: 10739683
    [Abstract] [Full Text] [Related]

  • 14. p53 overexpression is not an independent prognostic factor for patients with primary ovarian epithelial cancer.
    Eltabbakh GH, Belinson JL, Kennedy AW, Biscotti CV, Casey G, Tubbs RR, Blumenson LE.
    Cancer; 1997 Sep 01; 80(5):892-8. PubMed ID: 9307189
    [Abstract] [Full Text] [Related]

  • 15. Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study.
    Høgdall EV, Christensen L, Kjaer SK, Blaakaer J, Bock JE, Glud E, Nørgaard-Pedersen B, Høgdall CK.
    Cancer; 2003 Jul 01; 98(1):66-73. PubMed ID: 12833457
    [Abstract] [Full Text] [Related]

  • 16. [Relationship between expressions of p53, c-erbB2 genes, proliferating cell nuclear antigen and prognosis of patients with ovarian epithelial carcinoma].
    Li JD, Li MD, Li YF, Huang X, Liu JH, Liu FY, Zhang CQ.
    Ai Zheng; 2002 Mar 01; 21(3):292-6. PubMed ID: 12451998
    [Abstract] [Full Text] [Related]

  • 17. p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance.
    Laframboise S, Chapman W, McLaughlin J, Andrulis IL.
    Cancer J; 2000 Mar 01; 6(5):302-8. PubMed ID: 11079169
    [Abstract] [Full Text] [Related]

  • 18. Relations between immunologically different p53 forms, p21(WAF1) and PCNA expression in ovarian carcinomas.
    Harlozinska A, Bar JK, Montenarh M, Kartarius S.
    Oncol Rep; 2002 Mar 01; 9(6):1173-9. PubMed ID: 12375014
    [Abstract] [Full Text] [Related]

  • 19. Immunoreactivity evaluation of mutant p53 gene product with DNA ploidy pattern in colorectal carcinoma.
    Nasif WA, El-Emshaty HM, Tabll A, Elmasry SA, Attallah AM, Gad Elhak NA.
    Hepatogastroenterology; 2004 Mar 01; 51(58):1001-6. PubMed ID: 15239234
    [Abstract] [Full Text] [Related]

  • 20. Human kallikrein 8 (hK8/TADG-14) expression is associated with an early clinical stage and favorable prognosis in ovarian cancer.
    Shigemasa K, Tian X, Gu L, Tanimoto H, Underwood LJ, O'Brien TJ, Ohama K.
    Oncol Rep; 2004 Jun 01; 11(6):1153-9. PubMed ID: 15138549
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.